Table 2.
Treatment regimens and duration for metastatic colorectal cancer patients by line of therapy
| Treatment line and regimens | Patients, n (%) | Duration (days) | ||
|---|---|---|---|---|
| Mean | SD | Median | ||
| First line | N = 4418 | |||
| FOLFOX + bevacizumab | 1026 (23.2) | 197.5 | 115.5 | 188 |
| FOLFOX | 1003 (22.7) | 139.1 | 94.4 | 124 |
| FU/LV | 510 (11.5) | 130.9 | 111.1 | 97 |
| Oxaliplatin | 325 (7.4) | 126.9 | 92.3 | 104 |
| FU/LV + bevacizumab | 218 (4.9) | 180.2 | 153.2 | 132 |
| Oxaliplatin + bevacizumab | 216 (4.9) | 186.9 | 114.3 | 167 |
| FOLFIRI + bevacizumab | 194 (4.4) | 208.7 | 158.5 | 177 |
| FOLFIRI | 183 (4.1) | 149.2 | 114.0 | 136 |
| Bevacizumab | 151 (3.4) | 186.3 | 144.0 | 145 |
| FU | 150 (3.4) | 84.2 | 57.3 | 67 |
| Others | 442 (10.0) | 135.8 | 100.0 | 111 |
| Second line | N = 2534 | |||
| FOLFOX + bevacizumab | 449 (17.7) | 183.3 | 136.5 | 156 |
| FOLFIRI + bevacizumab | 353 (13.9) | 198.0 | 157.2 | 155 |
| FOLFIRI | 202 (8.0) | 128.0 | 83.5 | 111 |
| Irinotecan | 192 (7.6) | 126.4 | 93.0 | 97 |
| FU/LV + bevacizumab | 175 (6.9) | 181.1 | 143.1 | 139 |
| FOLFOX | 157 (6.2) | 132.6 | 74.3 | 120 |
| Cetuximab + irinotecan | 139 (5.5) | 155.5 | 98.8 | 135 |
| Oxaliplatin + bevacizumab | 127 (5.0) | 164.3 | 113.9 | 128 |
| Bevacizumab | 116 (4.6) | 194.1 | 207.3 | 133 |
| FU/LV | 98 (3.9) | 144.9 | 128.8 | 118 |
| Others | 526 (20.8) | 138.3 | 104.7 | 117 |
| Third line | N = 1370 | |||
| Cetuximab + irinotecan | 207 (15.1) | 152.0 | 124.7 | 125 |
| FOLFIRI + bevacizumab | 184 (13.4) | 195.0 | 158.8 | 153 |
| FOLFOX + bevacizumab | 104 (7.6) | 162.1 | 104.6 | 138 |
| FOLFIRI | 91 (6.6) | 119.7 | 105.3 | 96 |
| Irinotecan | 82 (6.0) | 123.0 | 89.2 | 89 |
| Cetuximab | 78 (5.7) | 131.5 | 137.3 | 101 |
| FU/LV + bevacizumab | 75 (5.5) | 199.1 | 201.3 | 132 |
| Bevacizumab | 71 (5.2) | 215.2 | 180.1 | 166 |
| Bevacizumab + irinotecan | 57 (4.2) | 167.2 | 109.9 | 134 |
| FOLFOX | 51 (3.7) | 120.8 | 71.5 | 98 |
| Others | 370 (30.7) | 135.9 | 112 | 110 |
FU 5-fluorouracil, FOLFOX 5-FU + LV+ oxaliplatin, FOLFIRI 5-FU + LV + irinotecan, LV leucovorin, SD standard deviation